[
 {
  "nct": "NCT00318461",
  "window": "on_treatment",
  "basis": "Adverse events were collected over 24 months of treatment"
 },
 {
  "nct": "NCT00375492",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00395746",
  "window": "calendar",
  "basis": "Adverse events were collected in a time span over 52 weeks."
 },
 {
  "nct": "NCT00500370",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00516074",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00518115",
  "window": "on_treatment",
  "basis": "On-therapy serious adverse events (SAEs) and non-serious AEs, defined as those that have a start date on or after the first day of study medication and within 56 days after the end of study medication, are reported."
 },
 {
  "nct": "NCT00577824",
  "window": "calendar",
  "basis": "Up to 30 weeks (Up to a 6 week screening period, and then 24 weeks on treatment)."
 },
 {
  "nct": "NCT00603239",
  "window": "calendar",
  "basis": "Adverse events were collected from baseline to endpoint, regardless of relationship to study drug."
 },
 {
  "nct": "NCT00620282",
  "window": "calendar",
  "basis": "The adverse events were collected from week 0 to week 12."
 },
 {
  "nct": "NCT00630825",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00658021",
  "window": "on_treatment",
  "basis": "Serious AEs: From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 32 weeks."
 },
 {
  "nct": "NCT00688701",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration"
 },
 {
  "nct": "NCT00696657",
  "window": "on_treatment",
  "basis": "A TEAE was defined as an event that had onset on or after the first date (week 0) on trial product and no later than 5 weeks after the last date on trial product (week 17)"
 },
 {
  "nct": "NCT00701935",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00712673",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration"
 },
 {
  "nct": "NCT00713830",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration, for up to 120 weeks"
 },
 {
  "nct": "NCT00715624",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration for up to 125 weeks"
 },
 {
  "nct": "NCT00763451",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration, for up to 112 weeks"
 },
 {
  "nct": "NCT00763815",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration, for up to 132 weeks"
 },
 {
  "nct": "NCT00765817",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00781937",
  "window": "on_treatment",
  "basis": "had onset on or after first day of randomised treatment and no later than 7 days after last day of randomised treatment."
 },
 {
  "nct": "NCT00782418",
  "window": "calendar",
  "basis": "Adverse experiences were collected from the time the consent is signed through the 14 day follow up period after all treatment periods were completed."
 },
 {
  "nct": "NCT00791479",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00838903",
  "window": "on_treatment",
  "basis": "On-treatment serious adverse events (SAEs) and non-serious AEs, defined as those events that had a start date on or after the first day of study medication and within 56 days after the end of study medication"
 },
 {
  "nct": "NCT00839527",
  "window": "on_treatment",
  "basis": "On-treatment serious adverse events (SAEs) and non-serious AEs, defined as those events that had a start date on or after the first day of study medication and within 56 days after the end of study medication"
 },
 {
  "nct": "NCT00845507",
  "window": "calendar",
  "basis": "Up to 16 weeks"
 },
 {
  "nct": "NCT00849017",
  "window": "on_treatment",
  "basis": "On-treatment serious adverse events (SAEs) and non-serious AEs, defined as those events that had a start date on or after the first day of study medication and within 56 days after the end of study medication"
 },
 {
  "nct": "NCT00849056",
  "window": "on_treatment",
  "basis": "On-treatment serious adverse events (SAEs) and non-serious AEs, defined as those events that had a start date on or after the first day of study medication and within 56 days after the end of study medication"
 },
 {
  "nct": "NCT00856609",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT00866658",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration"
 },
 {
  "nct": "NCT00882050",
  "window": "calendar",
  "basis": "AEs were collected on each subject from time of signed consent until 24 hours post surgery."
 },
 {
  "nct": "NCT00894322",
  "window": "calendar",
  "basis": "Day 1 to Week 12"
 },
 {
  "nct": "NCT00975286",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration"
 },
 {
  "nct": "NCT01001104",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01064687",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01098461",
  "window": "on_treatment",
  "basis": "On-therapy serious adverse events (SAEs)/non-serious AEs, with a start date on/after the first day of study medication (SM) and within 56 days after the end of SM"
 },
 {
  "nct": "NCT01136798",
  "window": "calendar",
  "basis": "6 weeks"
 },
 {
  "nct": "NCT01144338",
  "window": "calendar",
  "basis": "During study period up to 7.5 years"
 },
 {
  "nct": "NCT01147250",
  "window": "on_treatment",
  "basis": "Reported AEs are treatment emergent AEs that developed/worsened during 'on treatment period' (time from first administration of IMP up to 3 days after the last administration of IMP)."
 },
 {
  "nct": "NCT01149421",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01154933",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01169779",
  "window": "on_treatment",
  "basis": "First dose of study drug up to 3 days after the last dose administration"
 },
 {
  "nct": "NCT01179048",
  "window": "calendar",
  "basis": "Adverse events from randomisation (visit 3; month 0) and until follow up (visit 16; up to month 60+30 days of post-treatment follow-up)."
 },
 {
  "nct": "NCT01206101",
  "window": "calendar",
  "basis": "Adverse events were collected from week 0 to week 52."
 },
 {
  "nct": "NCT01234649",
  "window": "calendar",
  "basis": "Data collected over 5 years of trial"
 },
 {
  "nct": "NCT01255163",
  "window": "calendar",
  "basis": "Up to 18 months"
 },
 {
  "nct": "NCT01272219",
  "window": "calendar",
  "basis": "week 0 to week 70 (68 weeks of treatment period + 2 weeks of follow-up)."
 },
 {
  "nct": "NCT01272232",
  "window": "calendar",
  "basis": "Adverse events were recorded for up to 68 weeks."
 },
 {
  "nct": "NCT01324388",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01364584",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01392573",
  "window": "calendar",
  "basis": "Adverse events were captured from the time of consent untill 26 weeks of treatment, and were followed-up for 7 days after the final visit (upto overall 27 weeks)."
 },
 {
  "nct": "NCT01394952",
  "window": "calendar",
  "basis": "From Randomization to Study Completion (Up to 7 Years)"
 },
 {
  "nct": "NCT01473953",
  "window": "calendar",
  "basis": "The adverse events were collected in a timeframe of 7 days + 14 days follow up (Day 0 and up to 21 days after treatment)"
 },
 {
  "nct": "NCT01475734",
  "window": "calendar",
  "basis": "SAEs and non-serious AEs were collected from the time the participant consented to participate in the study through the end of the study"
 },
 {
  "nct": "NCT01505673",
  "window": "calendar",
  "basis": "6 months"
 },
 {
  "nct": "NCT01554618",
  "window": "on_treatment",
  "basis": "After the first dose of study medication in period through the end of the treatment in period + 90 days for SAEs"
 },
 {
  "nct": "NCT01557166",
  "window": "on_treatment",
  "basis": "have an onset date on or after the first day of randomised treatment and no later than 14 days after the last day of randomised treatment."
 },
 {
  "nct": "NCT01572740",
  "window": "calendar",
  "basis": "Adverse events were collected in a timeframe of 36 weeks + 7 days follow up."
 },
 {
  "nct": "NCT01617434",
  "window": "calendar",
  "basis": "Week 0 to Week 26 + 7 days follow up"
 },
 {
  "nct": "NCT01620489",
  "window": "calendar",
  "basis": "The adverse events were collected from Week 0 to Week 27±3 Days"
 },
 {
  "nct": "NCT01667900",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01720446",
  "window": "calendar",
  "basis": "Adverse events from the first trial-related activity after the subject had signed the informed consent (week -2) until the end of the posttreatment follow-up period (week 109)."
 },
 {
  "nct": "NCT01722240",
  "window": "calendar",
  "basis": "Safety data is collected for 56 weeks (4 weeks before randomization and 52 after randomization)"
 },
 {
  "nct": "NCT01722266",
  "window": "calendar",
  "basis": "12 weeks."
 },
 {
  "nct": "NCT01753362",
  "window": "calendar",
  "basis": "26 weeks"
 },
 {
  "nct": "NCT01769378",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01784965",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT01798706",
  "window": "on_treatment",
  "basis": "Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (time from the first dose of study drug up to 3 days after the last dose of study drug)."
 },
 {
  "nct": "NCT01800968",
  "window": "calendar",
  "basis": "All serious adverse events documented from baseline to day 210."
 },
 {
  "nct": "NCT01836523",
  "window": "on_treatment",
  "basis": "treatment emergent adverse event is defined as an event with onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment"
 },
 {
  "nct": "NCT01923181",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT01928329",
  "window": "calendar",
  "basis": "Up to 12 months."
 },
 {
  "nct": "NCT02020616",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT02054897",
  "window": "on_treatment",
  "basis": "From the first trial product administration (in week 0) till the date of the end-of-treatment follow-up visit (in week 35 + the 7-day visit window) or on the date of the last trial product administration plus 42 days"
 },
 {
  "nct": "NCT02073929",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT02098395",
  "window": "on_treatment",
  "basis": "From the first day of exposure to randomised treatment (week 0) to 7 days after the last day of randomised treatment (week 26)."
 },
 {
  "nct": "NCT02152371",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT02160990",
  "window": "calendar",
  "basis": "30 days"
 },
 {
  "nct": "NCT02229383",
  "window": "on_treatment",
  "basis": "Serious and Other adverse event data is reported for the on-treatment period."
 },
 {
  "nct": "NCT02229396",
  "window": "calendar",
  "basis": "From baseline (Day 1) up to Week 104 (28-week Treatment Period + 24-week Extension Period 1 + 52-week Extension Period 2)."
 },
 {
  "nct": "NCT02251431",
  "window": "calendar",
  "basis": "38 weeks from study initiation"
 },
 {
  "nct": "NCT02284009",
  "window": "on_treatment",
  "basis": "On-therapy AEs and SAEs were collected from start of study treatment up to 52-weeks"
 },
 {
  "nct": "NCT02288273",
  "window": "calendar",
  "basis": "18 weeks"
 },
 {
  "nct": "NCT02299388",
  "window": "unstated",
  "basis": ""
 },
 {
  "nct": "NCT02305381",
  "window": "on_treatment",
  "basis": "From the first dose of trial product until the end of the post-treatment follow-up period.The follow-up visit was scheduled to take place 5 weeks after the date of last dose of trial product"
 },
 {
  "nct": "NCT02417142",
  "window": "calendar",
  "basis": "24 weeks"
 },
 {
  "nct": "NCT02443155",
  "window": "calendar",
  "basis": "Weeks 0-80"
 },
 {
  "nct": "NCT02453711",
  "window": "on_treatment",
  "basis": "defined as any AE reported after first trial product administration and until last trial product administration with a 7-week follow-up period."
 },
 {
  "nct": "NCT02461589",
  "window": "on_treatment",
  "basis": "Treatment-emergent adverse events (TEAEs) were defined as events recorded from the first dose of trial product and until completion of the post-treatment follow-up visit (7 weeks)."
 },
 {
  "nct": "NCT02465515",
  "window": "on_treatment",
  "basis": "On-therapy non-SAEs and SAEs were reported on or after treatment start date and within 56 days after treatment stop date (Up to 2.7 years)"
 },
 {
  "nct": "NCT02496611",
  "window": "calendar",
  "basis": "Adverse event and serious adverse event data was collected from Baseline to Week 52."
 },
 {
  "nct": "NCT02548585",
  "window": "on_treatment",
  "basis": "From Day 1 to follow-up period (28 days after the last study dose for each cohort [approximately 60 days])"
 },
 {
  "nct": "NCT02597049",
  "window": "calendar",
  "basis": "Baseline to end of study (up to 24 weeks)"
 },
 {
  "nct": "NCT02647944",
  "window": "calendar",
  "basis": "16 weeks"
 },
 {
  "nct": "NCT02664441",
  "window": "calendar",
  "basis": "Double-Blind Randomized Phase - From Study Visit 1 (0 weeks) through end of Study Visit 4 (36 weeks)"
 },
 {
  "nct": "NCT02692716",
  "window": "on_treatment",
  "basis": "SAEs and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT02750410",
  "window": "calendar",
  "basis": "Up to 52 weeks"
 },
 {
  "nct": "NCT02759107",
  "window": "calendar",
  "basis": "Baseline to end of study (Up to 57 days)"
 },
 {
  "nct": "NCT02765399",
  "window": "on_treatment",
  "basis": "During 16 weeks of Liraglutide therapy"
 },
 {
  "nct": "NCT02777073",
  "window": "on_treatment",
  "basis": "throughout patient participation period of 8hr and up to 72 hrs follow-up after the dose administration"
 },
 {
  "nct": "NCT02827708",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT02863419",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT02906930",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT02918279",
  "window": "on_treatment",
  "basis": "'On-treatment' period: Events with onset date between the first day of trial product administration and any of the following date, whichever came first: 1) 14 days after the last day on trial product"
 },
 {
  "nct": "NCT02953665",
  "window": "calendar",
  "basis": "Adverse Event collection commenced upon signing of consent at Screening and occurred at Baseline Week 1, Week 2, Week 6, Week 14, Week 28, Week 38, Week 54, and at follow-up Week 58."
 },
 {
  "nct": "NCT02962492",
  "window": "calendar",
  "basis": "throughout the study (12 weeks)"
 },
 {
  "nct": "NCT02963766",
  "window": "calendar",
  "basis": "Up To 56 Weeks"
 },
 {
  "nct": "NCT02963922",
  "window": "on_treatment",
  "basis": "From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days."
 },
 {
  "nct": "NCT02963935",
  "window": "on_treatment",
  "basis": "From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days."
 },
 {
  "nct": "NCT02964247",
  "window": "on_treatment",
  "basis": "Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product."
 },
 {
  "nct": "NCT02970942",
  "window": "on_treatment",
  "basis": "All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during on-treatment period."
 },
 {
  "nct": "NCT02973100",
  "window": "calendar",
  "basis": "Up to 22 weeks"
 },
 {
  "nct": "NCT02973321",
  "window": "on_treatment",
  "basis": "Reported AEs were treatment-emergent AEs that is AEs that developed/worsened or became serious during the 26-week'treatment period' (Treatment period was defined as time from the first injection of IMP up to last injection of IMP + 3 days)."
 },
 {
  "nct": "NCT02975297",
  "window": "calendar",
  "basis": "10 weeks"
 },
 {
  "nct": "NCT02981069",
  "window": "calendar",
  "basis": "Baseline to 6 months"
 },
 {
  "nct": "NCT03018028",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT03021187",
  "window": "on_treatment",
  "basis": "Serious adverse events and other AEs were based on the on-treatment observation period, i.e., the time period when a participant was on treatment with trial product"
 },
 {
  "nct": "NCT03029351",
  "window": "calendar",
  "basis": "52 weeks"
 },
 {
  "nct": "NCT03038620",
  "window": "calendar",
  "basis": "For the entire duration of the study: 40 weeks."
 },
 {
  "nct": "NCT03041792",
  "window": "calendar",
  "basis": "From Baseline (Visit 3, Study Day -1 and Day 0) to Day 73."
 },
 {
  "nct": "NCT03048578",
  "window": "calendar",
  "basis": "1 year"
 },
 {
  "nct": "NCT03086330",
  "window": "calendar",
  "basis": "Week 0 to week 30 (treatment period) + 42 days (follow-up period). All the reported adverse events (AEs) are TEAEs."
 },
 {
  "nct": "NCT03115424",
  "window": "calendar",
  "basis": "Adverse Events were collected from baseline to end of study, approximately 36 months"
 },
 {
  "nct": "NCT03131687",
  "window": "calendar",
  "basis": "Up To 34 Weeks"
 },
 {
  "nct": "NCT03158805",
  "window": "calendar",
  "basis": "Through study completion, for the total duration of the trial, including up to 27 days of screening , the 40 study treatment weeks and one week of follow up"
 },
 {
  "nct": "NCT03235050",
  "window": "calendar",
  "basis": "Adverse events were collected from time of first IP dose throughout the 54-week treatment period and including the 28-day follow-up period. Serious AEs were recorded from the time of signature of informed consent."
 },
 {
  "nct": "NCT03244800",
  "window": "on_treatment",
  "basis": "From Day 1 through 7 to 14 days after the last dose of study drug (approximately 64 days)"
 },
 {
  "nct": "NCT03279731",
  "window": "calendar",
  "basis": "from the beginning to the end of the 17 week trial"
 },
 {
  "nct": "NCT03311724",
  "window": "calendar",
  "basis": "Baseline through end of study (Up to 15 weeks)."
 },
 {
  "nct": "NCT03322631",
  "window": "calendar",
  "basis": "Up To 85 days"
 },
 {
  "nct": "NCT03353350",
  "window": "calendar",
  "basis": "were collected from the date of signing the Informed Consent Form (ICF) until the end of the study, defined by the protocol for that participant as Week 62."
 },
 {
  "nct": "NCT03444584",
  "window": "on_treatment",
  "basis": "Day 1 through 28 days after the last dose of MEDI0382 (approximately 8 weeks)"
 },
 {
  "nct": "NCT03480022",
  "window": "calendar",
  "basis": "36 weeks"
 },
 {
  "nct": "NCT03486392",
  "window": "calendar",
  "basis": "Up to 30 Weeks"
 },
 {
  "nct": "NCT03496298",
  "window": "on_treatment",
  "basis": "From time of first injection of investigational medicinal product (IMP) to the last injection of IMP + 30 days (i.e., up to maximum duration of 31.5 months)."
 },
 {
  "nct": "NCT03523273",
  "window": "calendar",
  "basis": "Adverse events will be collected from baseline to end of study participation for a total of approximately 18 weeks on all participants."
 },
 {
  "nct": "NCT03548935",
  "window": "on_treatment",
  "basis": "TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to randomized treatment and no later than the date of last dose + 7 weeks."
 },
 {
  "nct": "NCT03548987",
  "window": "on_treatment",
  "basis": "TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than the date of last dose + 7 weeks."
 },
 {
  "nct": "NCT03550378",
  "window": "calendar",
  "basis": "Day 1 through Day 60"
 },
 {
  "nct": "NCT03552757",
  "window": "calendar",
  "basis": "Week 0 to week 75."
 },
 {
  "nct": "NCT03555994",
  "window": "on_treatment",
  "basis": "Post dosing (Day 1) to final follow-up (28 Days post last dose)"
 },
 {
  "nct": "NCT03574597",
  "window": "in_trial",
  "basis": "AEs are reported based on data from in-trial observation period."
 },
 {
  "nct": "NCT03596177",
  "window": "on_treatment",
  "basis": "Day 17 through 28 days post last dose (approximately 14 months)"
 },
 {
  "nct": "NCT03611582",
  "window": "on_treatment",
  "basis": "TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than the date of last dose + 7 weeks."
 },
 {
  "nct": "NCT03645421",
  "window": "on_treatment",
  "basis": "Treatment-emergent AEs were collected from Day 1 of treatment up to 14 days after the last dose of IP (approximately 9 weeks)."
 },
 {
  "nct": "NCT03693430",
  "window": "on_treatment",
  "basis": "TEAE defined as an event that had onset date (or increase in severity) on or after the first day of exposure to randomized treatment and no later than the date of last dose + 7 weeks."
 },
 {
  "nct": "NCT03712098",
  "window": "calendar",
  "basis": "8 months"
 },
 {
  "nct": "NCT03713684",
  "window": "on_treatment",
  "basis": "Time frame for reporting of treatment emergent adverse events (TEAEs) was from first injection of Investigational Medicinal Product (IMP) up to 30 days after the last injection of the IMP (i.e. up to Week 60)."
 },
 {
  "nct": "NCT03743025",
  "window": "calendar",
  "basis": "beginning at the time of consent and continued through the final assessment occurring 30 days after discharge from the hospital, up to 42 days postoperatively."
 },
 {
  "nct": "NCT03745937",
  "window": "on_treatment",
  "basis": "Baseline (Day -1) through 28 days post last dose (approximately up to 5 months)"
 },
 {
  "nct": "NCT03770728",
  "window": "on_treatment",
  "basis": "Time frame for reporting of treatment emergent adverse events (TEAEs) was from first injection of investigational medicinal product (IMP) up to 30 days after the last injection of the IMP (i.e. up to Week 34)."
 },
 {
  "nct": "NCT03811574",
  "window": "on_treatment",
  "basis": "Adverse events were defined as \"treatment-emergent\" (TEAE), if the onset of the event occurs in the on-treatment period."
 },
 {
  "nct": "NCT03819153",
  "window": "in_trial",
  "basis": "The safety evaluation was based on the FAS using the in-trial observation period which is defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent"
 },
 {
  "nct": "NCT03856047",
  "window": "on_treatment",
  "basis": "TEAE is defined as an event that had onset date during the on-treatment period. On-treatment period was from the date of first trial product administration to date of last trial product administration"
 },
 {
  "nct": "NCT03914326",
  "window": "calendar",
  "basis": "From Week 0 up to Week 265"
 },
 {
  "nct": "NCT03951753",
  "window": "calendar",
  "basis": "Up to Week 32"
 },
 {
  "nct": "NCT03954834",
  "window": "calendar",
  "basis": "Baseline to end of Safety follow-up (up to 44 weeks)"
 },
 {
  "nct": "NCT03985293",
  "window": "calendar",
  "basis": "Baseline up to Week 21"
 },
 {
  "nct": "NCT03987451",
  "window": "on_treatment",
  "basis": "On-treatment period which started on the date of first administration of trial product and ended on the date of whatever comes first of: a) last dose of trial product + 49 days"
 },
 {
  "nct": "NCT04019197",
  "window": "on_treatment",
  "basis": "Adverse event data were collected for participants during the time when each participant was receiving active drug or placebo (32 weeks)."
 },
 {
  "nct": "NCT04019561",
  "window": "calendar",
  "basis": "Treatment Emergent Adverse Events and Serious Adverse Events are summarized from the first dose of IP throughout the treatment period of 19 weeks and including the follow-up period of 4 weeks - a total of 23 weeks."
 },
 {
  "nct": "NCT04039503",
  "window": "calendar",
  "basis": "Baseline, 17 Months"
 },
 {
  "nct": "NCT04074161",
  "window": "on_treatment",
  "basis": "TEAEs defined as AEs, with the onset of the event occurred in the on-treatment period."
 },
 {
  "nct": "NCT04081337",
  "window": "calendar",
  "basis": "Baseline Through End of Safety Follow-up (Up to 22 Weeks)"
 },
 {
  "nct": "NCT04102189",
  "window": "on_treatment",
  "basis": "The on-treatment period was defined as the interval from first to last trial product administration plus 7 weeks of follow-up"
 },
 {
  "nct": "NCT04109547",
  "window": "on_treatment",
  "basis": "TEAE was defined as an AE with onset in the on-treatment observation period."
 },
 {
  "nct": "NCT04126603",
  "window": "calendar",
  "basis": "24 weeks"
 },
 {
  "nct": "NCT04153929",
  "window": "on_treatment",
  "basis": "From first intake of any trial drug until last intake of any trial drug (planned: 16 weeks) + residual effect period (BI 456906: 28 days, Semaglutide: 35 days), up to 159 days."
 },
 {
  "nct": "NCT04166773",
  "window": "calendar",
  "basis": "Baseline Up to Week 56"
 },
 {
  "nct": "NCT04184622",
  "window": "calendar",
  "basis": "Baseline up to Week 193"
 },
 {
  "nct": "NCT04199728",
  "window": "on_treatment",
  "basis": "A follow-up communication was scheduled 30 days (±5 days) after the participant's last treatment day. Participants could be assessed up to 54 days for adverse events."
 },
 {
  "nct": "NCT04235959",
  "window": "calendar",
  "basis": "Up To 43 Weeks"
 },
 {
  "nct": "NCT04251156",
  "window": "on_treatment",
  "basis": "All presented AEs are TEAEs, defined as an event with onset during the on-treatment observation period."
 },
 {
  "nct": "NCT04311411",
  "window": "calendar",
  "basis": "Baseline up to 10 Weeks"
 },
 {
  "nct": "NCT04515576",
  "window": "calendar",
  "basis": "Baseline through final follow-up at Day 57"
 },
 {
  "nct": "NCT04515849",
  "window": "on_treatment",
  "basis": "Screening throughout the treatment period and including the follow-up period (28 days post last dose), an average of 37 weeks."
 },
 {
  "nct": "NCT04552470",
  "window": "on_treatment",
  "basis": "Day 1 of dosing up to approximately 4 weeks after last dose (up to maximum of approximately 12 weeks)"
 },
 {
  "nct": "NCT04560998",
  "window": "on_treatment",
  "basis": "All presented adverse events are treatment emergent adverse events (TEAEs). A Treatment Emergent Adverse Event (TEAE) is defined as an AE with onset in the on-treatment observation period."
 },
 {
  "nct": "NCT04591626",
  "window": "calendar",
  "basis": "Baseline Through End of Safety Follow-Up (Up To 32 Weeks)"
 },
 {
  "nct": "NCT04596631",
  "window": "on_treatment",
  "basis": "TEAE is defined as an AE with onset in the on-treatment observation period."
 },
 {
  "nct": "NCT04617275",
  "window": "calendar",
  "basis": "Baseline through follow-up (Day 112-119)."
 },
 {
  "nct": "NCT04624672",
  "window": "calendar",
  "basis": "6 months"
 },
 {
  "nct": "NCT04657003",
  "window": "calendar",
  "basis": "Baseline through Week 76"
 },
 {
  "nct": "NCT04657016",
  "window": "calendar",
  "basis": "Baseline up to week 76"
 },
 {
  "nct": "NCT04660643",
  "window": "calendar",
  "basis": "Week 0 to 36 for the open-label lead-in period arm, Week 36 to 92 for the double-blind study period arms."
 },
 {
  "nct": "NCT04667377",
  "window": "on_treatment",
  "basis": "From first drug administration until last drug administration, plus 28 days residual effect period (REP), up to 360 days."
 },
 {
  "nct": "NCT04707313",
  "window": "on_treatment",
  "basis": "From first dose of study intervention on Day 1 up to 28-35 days after last dose of study treatment"
 },
 {
  "nct": "NCT04741074",
  "window": "calendar",
  "basis": "9 months"
 },
 {
  "nct": "NCT04771273",
  "window": "on_treatment",
  "basis": "[Serious Adverse Events], [Other Adverse Events]: From first study drug administration until last study drug administration plus 28 days of residual effect period (REP), up to 365 days."
 },
 {
  "nct": "NCT04779697",
  "window": "calendar",
  "basis": "12 weeks"
 },
 {
  "nct": "NCT04788511",
  "window": "on_treatment",
  "basis": "A TEAEs was defined as an event that had onset during the on-treatment period (date of first trial product administration to date of last trial product administration"
 },
 {
  "nct": "NCT04844918",
  "window": "calendar",
  "basis": "Baseline Through Safety Follow-Up (Up To 76 Weeks)"
 },
 {
  "nct": "NCT04847557",
  "window": "calendar",
  "basis": "Baseline Up To 162 Weeks"
 },
 {
  "nct": "NCT04862234",
  "window": "calendar",
  "basis": "Information on adverse events was collected from the time that individuals gave consent to participate in the study through the final assessment at hospital discharge, up to 5 days postoperatively."
 },
 {
  "nct": "NCT04865770",
  "window": "on_treatment",
  "basis": "A TEAE was defined as an AE with onset in all observed data points from first date of study product until permanent discontinuation of treatment."
 },
 {
  "nct": "NCT04867785",
  "window": "in_trial",
  "basis": "All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication."
 },
 {
  "nct": "NCT04881760",
  "window": "in_trial",
  "basis": "All randomized participants who received at least one dose of study drug, regardless of adherence to study drug."
 },
 {
  "nct": "NCT04889157",
  "window": "on_treatment",
  "basis": "Baseline up to 35 days after last dose (Day 91)"
 },
 {
  "nct": "NCT04971785",
  "window": "calendar",
  "basis": "All-cause mortality and Adverse events: Up to 72 weeks plus 35 days"
 },
 {
  "nct": "NCT04982575",
  "window": "on_treatment",
  "basis": "On treatment observation period starts at date of first dose of trial product \\& ends at first date of any of following; date of last dose of trial product +35 days for AEs"
 },
 {
  "nct": "NCT04998136",
  "window": "on_treatment",
  "basis": "Adverse events will be defined as \"treatment-emergent\" (TEAE), if the onset of the event occurs in the on-treatment period."
 },
 {
  "nct": "NCT05024032",
  "window": "calendar",
  "basis": "Baseline Through Safety Follow-Up (Up To Week 56)"
 },
 {
  "nct": "NCT05035095",
  "window": "on_treatment",
  "basis": "Treatment emergent adverse events (TEAEs): events that had onset date during on-treatment period, time period in which participants was considered exposed to trial product."
 },
 {
  "nct": "NCT05040971",
  "window": "on_treatment",
  "basis": "Treatment emergent adverse events (TEAEs): events that had onset date during on-treatment period, time period in which participants was considered exposed to trial product."
 },
 {
  "nct": "NCT05048719",
  "window": "calendar",
  "basis": "Baseline Through Safety Follow-Up (Up To Week 28)"
 },
 {
  "nct": "NCT05051579",
  "window": "in_trial",
  "basis": "All randomized participants who received at least one dose of study drug regardless of adherence to study drug."
 },
 {
  "nct": "NCT05064735",
  "window": "on_treatment",
  "basis": "A TEAEs was defined as an event that had onset during the on-treatment period (date of first trial product administration to date of last trial product administration"
 },
 {
  "nct": "NCT05086445",
  "window": "calendar",
  "basis": "Baseline Through Follow-Up (Up To Week 15)"
 },
 {
  "nct": "NCT05132088",
  "window": "on_treatment",
  "basis": "Presented AEs are TEAEs, defined as an event with onset during on-treatment observation period. On-treatment is date of first trial product administration (week 0) to date of last trial product administration (week 68)"
 },
 {
  "nct": "NCT05144984",
  "window": "on_treatment",
  "basis": "All presented AEs are TEAEs, defined as an event with onset during the on treatment period."
 },
 {
  "nct": "NCT05260021",
  "window": "in_trial",
  "basis": "All randomised participants who received at least one dose of study drug were included in safety analyses, regardless of adherence or use of rescue medication."
 },
 {
  "nct": "NCT05347147",
  "window": "calendar",
  "basis": "Adverse event data were collected over a period of up to 30 weeks, from the signing of the informed consent form to the end of the follow-up period."
 },
 {
  "nct": "NCT05364931",
  "window": "calendar",
  "basis": "From first dose on Day 1 up to approximately 52 weeks."
 },
 {
  "nct": "NCT05412004",
  "window": "calendar",
  "basis": "Baseline to Follow-up (Up To 56 Weeks)"
 },
 {
  "nct": "NCT05486065",
  "window": "on_treatment",
  "basis": "On-treatment oberservation period define as time points from first drug date until the first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days."
 },
 {
  "nct": "NCT05520775",
  "window": "calendar",
  "basis": "From the Baseline medical visit through follow-up, a total of up to 12 weeks."
 },
 {
  "nct": "NCT05530577",
  "window": "calendar",
  "basis": "From the Baseline medical visit through follow-up, a total of up to 12 weeks."
 },
 {
  "nct": "NCT05537233",
  "window": "calendar",
  "basis": "from signing consent from till end of the study (i.e 26 weeks)"
 },
 {
  "nct": "NCT05548647",
  "window": "on_treatment",
  "basis": "From enrollment until end of treatment, up to 72 weeks"
 },
 {
  "nct": "NCT05564117",
  "window": "on_treatment",
  "basis": "All presented adverse events (AEs) are treatment emergent adverse events defined as an event with onset during on-treatment observation period."
 },
 {
  "nct": "NCT05646706",
  "window": "calendar",
  "basis": "From baseline (week 0) to end of study (week 81)"
 },
 {
  "nct": "NCT05649137",
  "window": "in_trial",
  "basis": "All presented AEs are treatment emergent AEs (TEAEs). A TEAE is defined as an adverse event which occured during the in-trial period."
 },
 {
  "nct": "NCT05691712",
  "window": "in_trial",
  "basis": "All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue medication."
 },
 {
  "nct": "NCT05696847",
  "window": "calendar",
  "basis": "Baseline Up To 14 Weeks"
 },
 {
  "nct": "NCT05869903",
  "window": "calendar",
  "basis": "Baseline Up to Week 74"
 },
 {
  "nct": "NCT05872620",
  "window": "calendar",
  "basis": "Baseline Up to Week 74"
 },
 {
  "nct": "NCT05891496",
  "window": "on_treatment",
  "basis": "All presented adverse events (AEs) are treatment emergent adverse events (TEAEs), defined as an event with onset during the on-treatment period."
 },
 {
  "nct": "NCT05931380",
  "window": "calendar",
  "basis": "Baseline up to end of follow-up (up to 74 weeks)"
 },
 {
  "nct": "NCT05963022",
  "window": "in_trial",
  "basis": "All randomized participants who received at least one dose of study drug regardless of adherence to study drug or initiation of rescue antihyperglycemic medication."
 },
 {
  "nct": "NCT05971940",
  "window": "calendar",
  "basis": "Baseline to end of safety follow-up (up to 42 weeks)"
 },
 {
  "nct": "NCT06023095",
  "window": "calendar",
  "basis": "Baseline up to 182 Days"
 },
 {
  "nct": "NCT06041217",
  "window": "calendar",
  "basis": "From baseline (week 0) to end of study (week 49)"
 },
 {
  "nct": "NCT06109311",
  "window": "calendar",
  "basis": "Baseline to end of safety follow-up (up to 42 weeks)"
 },
 {
  "nct": "NCT06124807",
  "window": "calendar",
  "basis": "Baseline up to Week 56"
 }
]